TrialClinical cancer research : an official journal of the American Association for Cancer Research2025

Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas.

Faye M Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.